A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1123

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Docetaxel
BIOLOGICAL: Sacituzumab Tirumotecan

Sponsor

Merck Sharp & Dohme LLC